Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

906
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
906
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

321
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
321
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

310
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
310
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

336
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
336

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Longitudinal, Linked Maternal-Infant Cohorts using the Epic Cosmos Electronic Health Record Dataset.

medRxiv : the preprint server for health sciences·2026
Same author

Co-intelligence: a proposal for human-artificial intelligence collaboration for large language models in medical research.

The Lancet. Digital health·2026
Same author

Larger forest patches have greater per-area productivity.

Nature ecology & evolution·2026
Same author

Artificial Intelligence in Peripheral Artery Disease: A Science Advisory From the American Heart Association.

Circulation. Population health and outcomes·2026
Same author

Physician-Reported Safety Outcomes of AI-Generated Hospital Course Summaries.

JAMA network open·2026
Same author

Powering RCTs for Marginal Effects With GLMs Using Prognostic Score Adjustment.

Statistics in medicine·2026
Same journal

Trust, Reproducibility, and Progress: The Roles of Independent Blind Prediction and Assessment and Benchmarking in Computational Biology.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026
Same journal

The Evolving Cyberinfrastructure at the National Institutes of Health to Support Data and AI in Biomedical Research.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026
Same journal

Applications of AI & ML in Biomanufacturing of Cell and Gene Therapies.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026
Same journal

AI for Health: Leveraging Artificial Intelligence to Revolutionize Healthcare.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026
Same journal

Workshop Introduction: Advances of AI Methods in Single Cell Spatial Omics.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026
Same journal

DRIVE-KG: Enhancing variant-phenotype association discovery in understudied complex diseases using heterogeneous knowledge graphs.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

2.1K

DISCOVERING PATIENT PHENOTYPES USING GENERALIZED LOW RANK MODELS.

Alejandro Schuler1, Vincent Liu, Joe Wan

  • 1Center for Biomedical Informatics Research, Stanford University, 1265 Welch Road, Stanford, CA, 94305., USA, aschuler@stanford.edu.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|January 19, 2016
PubMed
Summary
This summary is machine-generated.

Generalized Low Rank Modeling (GLRM) accelerates patient phenotype discovery by overcoming data challenges in electronic health records. This machine learning approach successfully identifies known and potential patient groups across diverse healthcare datasets.

More Related Videos

Probing the Limits of Egg Recognition Using Egg Rejection Experiments Along Phenotypic Gradients
07:34

Probing the Limits of Egg Recognition Using Egg Rejection Experiments Along Phenotypic Gradients

Published on: August 22, 2018

8.7K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

2.3K

Related Experiment Videos

Last Updated: Mar 27, 2026

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

2.1K
Probing the Limits of Egg Recognition Using Egg Rejection Experiments Along Phenotypic Gradients
07:34

Probing the Limits of Egg Recognition Using Egg Rejection Experiments Along Phenotypic Gradients

Published on: August 22, 2018

8.7K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

2.3K

Area of Science:

  • Computational biology
  • Medical informatics
  • Machine learning applications in healthcare

Background:

  • Clinical practice relies on identifying patient phenotypes for tailored treatments.
  • Traditional phenotype discovery is slow, labor-intensive, and often heuristic.
  • Challenges like missing data and heterogeneity hinder machine learning-based phenotype discovery in electronic health records.

Purpose of the Study:

  • To introduce Generalized Low Rank Modeling (GLRM) as a flexible framework for accelerating phenotype discovery.
  • To demonstrate GLRM's capability in overcoming data limitations in electronic health records.
  • To identify known and novel patient phenotypes in diverse datasets.

Main Methods:

  • Applied Generalized Low Rank Modeling (GLRM) to two distinct patient datasets.
  • Utilized the Healthcare Cost and Utilization Project National Inpatient Sample (NIS) with millions of hospitalization records.
  • Analyzed a local autism spectrum disorder cohort dataset with granular electronic health record features, including clinical notes.

Main Results:

  • GLRM effectively handled missing data, sparsity, and heterogeneity in both large-scale administrative and granular clinical datasets.
  • The model successfully captured known patient phenotypes within the analyzed data.
  • Putative, or potential, phenotypes were also identified, suggesting new avenues for clinical research.

Conclusions:

  • Generalized Low Rank Modeling (GLRM) offers a robust solution for phenotype discovery in complex healthcare data.
  • This machine learning approach can significantly accelerate the identification of patient subgroups.
  • GLRM demonstrates potential for improving clinical decision-making and treatment strategies by revealing nuanced patient phenotypes.